Table 3 Antiviral efficiency of RetroMAD1 against SARS-CoV-2.

From: Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1

Test compounds

Concentration (µg/mL)

aLog10 CCID50 virus per 0.2 mL

bEC90 (µg/mL)

RetroMAD1

400

2.5

157

300

2.67

200

3.5

150

3.67

100

3.67

75

4

50

4.3

37.5

4

Remdesivir

1

1.67

0.006

0.1

2.67

0.01

3.5

0.001

3.67

Virus control

NA

4.4

NA

  1. The data presented here represent the mean values obtained from three biological replicates. Each well was considered positive for virus presence if any Cytopathic Effect (CPE) was observed in comparison to the uninfected control. Assessment of Vero-76 cells was conducted on day 7 and confirmed on day 10.
  2. NA is not applicable.
  3. The concentrations of RetroMAD1 that demonstrated equally effective inhibition of SARS-CoV-2 replication as Remdesivir at 0.1 µg/mL are in italics.
  4. aTiter results originate from the virus yield reduction assay.
  5. bEC90 denotes the 90% effective concentration, which is the concentration required to reduce virus yield by 1 − log10, as determined through regression analysis.
Back to article page